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Abstract
JKA97, a benzylidene analog of harmine, has been found to be a promising drug candidate for human cancer therapy,
although the underlying molecular mechanisms have not been fully demonstrated. In this study, we evaluated the effects of
JKA97 on human breast cancer cells in vitro and in vivo. JKA97 inhibited the growth and proliferation of MCF7 (p53 wild-
type), MCF7 (p53 knockdown), and MDA-MB-468 (p53 mutant) cells in a dose-dependent manner. Treatment with JKA97
arrested breast cancer cells in G1 phase and induced apoptosis. JKA97 also significantly suppressed the growth of MCF7 and
MDA-MB-468 xenograft tumors. It regulated the expression levels of G1 phase regulators, such as p21, p27, cyclinE, and
cylinD1. JKA97 activated p21 transcription, independent of p53, but had little effect on p21 protein stability/degradation. In
summary, our results suggest that JKA97 inhibits human breast cancer cell growth through activating p21, independent of
p53, which provides a basis for developing this compound as a novel drug for human breast cancer therapy.
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Introduction
Breast cancer is one of the most commonly diagnosed cancers
and the leading causes of cancer death in women worldwide.
According to statistical data from GLOBOCAN, about 1.38 million
new patients were diagnosed with breast cancer and about 458,400
died worldwide from the disease in 2008 [1]. In the past two
decades, death rates from breast cancer have declined due to early
detection, increased awareness and improved or novel therapies.
However, certain forms of breast cancer are particularly aggressive
and present a poor prognosis. Patients with advanced-stage or
relapsed breast cancer often show modest response to clinically
existing therapies and may even exhibit resistance to conventional
chemotherapeutic agents [2–4]. The paucity and inefficacy of
practicable therapeutics makes successful treatment of breast cancer
a challenge and necessitates the discovery of alternative chemo-
therapeutic drugs with novel anti-cancer mechanisms.
Natural product-oriented synthetic derivatives have played an
important role in anti-cancer drug discovery [5,6]. Several widely-
used chemotherapeutic agents such as paclitaxel and actinomycin
C were originally developed from natural products. Harmine, a b-
carboline alkaloid obtained from the seeds of the poisonous plant
Peganum harmala, has been used medically for some time as an anti-
hypertensive drug; acting by reversibly inhibiting monoamine
oxidase A. Studies in the past decade revealed that harmine also
possessed potent anti-proliferative and cytotoxic properties [7,8].
JKA97, also referred as methoxy-1-styryl-9H-pyrido-[3,4-b]-
indole (MW: 286.35; Fig. 1A), is a benzylidene analog of harmine
[9,10]. A recent report showed that JKA97 could induce apoptosis
of colon and liver cancer cells in vitro and in vivo by a Bax-
dependent and p53-independent mechanism [10]. However, the
anti-cancer activities of JKA97 on other types of cancer and the
precise molecular mechanisms of the compound are not well
understood. In the present study, we explored the anti-tumor
activities of JKA97 against breast cancer cells with various genetic
backgrounds, and attempted to further elucidate the possible
mechanisms of action, providing a basis for future development of
this agent as human breast cancer therapy.
Results
JKA97 decreases breast cancer cell growth in vitro
JKA97 was evaluated for its effects on breast cancer cell viability
in vitro by use of the MTT assay. Three human breast cancer cell
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4lines representing three different genetic backgrounds (MCF7/p53
wild-type; MCF7/p53 knockdown, and MDA-MB-468/p53
mutant) were exposed to various concentrations of the test
compound (0, 1, 2.5, 5, 10, 25, and 50 mM) for 72 hrs, and cell
survival percentages were determined. As seen in Fig. 1B, the
compound demonstrated IC50 values of less than 20 mM (6.6–
19.0 mM). The MDA-MB-468 and MCF7 p53KD cells appeared
to be more sensitive to the compound than MCF7 cells.
JKA97 inhibits breast cancer cell proliferation in vitro
Similar to the effects on cell survival, JKA97 inhibited cell
proliferation in a dose-dependent manner (Fig. 1C). Significant
anti-proliferative effects were seen in all three cell types with
various p53 backgrounds. At a concentration of 20 mM, JKA97
inhibited the proliferation by about 35%, 35%, and 45%, in
MCF7, MDA-MB-468, and MCF7 p53KD cells, respectively.
JKA97 induces apoptosis of breast cancer cells in vitro
In addition to inhibiting proliferation, JKA97 also induced
apoptosis in breast cancer cells. As illustrated in Fig. 1D, all three
of the examined breast cancer cell lines exhibited a significant
increase (P,0.05) in apoptosis following exposure to a 20 mM
concentration of the compound. In the MCF7, MDA-MB-468,
and MCF7 p53KD cells, a 20 mM JKA97 increased the apoptotic
index 3.9-fold, 5-fold, and 4.2-fold, respectively, as compared to
that in control cells.
JKA97 causes G1 phase arrest in breast cancer cells in
vitro
We also observed that JKA97 inhibited cell cycle progression,
leading to arrest in the G1 phase of the cell cycle in a dose-
dependent manner in all three cell lines (Fig. 1E). In both MCF7
and MCF7 p53KD cells, even at the 5 mM concentration, JKA97
led to a significant (P,0.05) increase in the number of cells in the
G1 phase. At the 20 mM concentration, a majority of the cells
were arrested in the G1 phase (P,0.05).
JKA97 decreases xenograft tumors growth in vivo
To determine whether the compound can also exert anti-cancer
effects in vivo, JKA97 was administered to nude mice bearing
Figure 1. In vitro anticancer activities of JKA97 against breast cancer cells. (A) Chemical structure of JKA97. (B) Concentrations of JKA97
inducing 50% growth inhibition (IC50) in breast cancer cells, relative to the corresponding controls, based on the MTT assay. MCF7, MDA-MB-468, and
MCF7 p53KD cells were exposed to various concentrations of JKA97 for 72 hrs. (C) Anti-proliferative effects of JKA97 on breast cancer cells. Cells were
exposed to various concentrations of JKA97 for 48 hrs, followed by the BrdUrd incorporation assay. The proliferation index was calculated against
untreated control cells (*P,0.05). (D) Induction of apoptosis in breast cancer cells by JKA97. Cells were exposed to various concentrations of JKA97
for 24 hrs, followed by measurement of apoptosis by Annexin V assay. The apoptotic index was calculated against untreated control cells (*P,0.05).
(E) Effects of JKA97 on the cell cycle distribution of breast cancer cells. Cells were exposed to various concentrations of JKA97 for 24 hrs, followed by
measurement DNA contents by flow cytometry. The cell cycle distribution was evaluated by comparing with that of control cells (*P,0.05). All the
assays were performed in triplicate. Results were from at least three separate, repeated experiments.
doi:10.1371/journal.pone.0034303.g001
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model, the high dose of JKA97 (25 mg/kg) inhibited tumor growth
by about 60% (P,0.05) on day 18, with the low dose (5 mg/kg) also
leading to significant tumor growth inhibition (50%, p,0.05;
Fig. 2A1). The in vivo anticancer activity of JKA97 was further
investigated in MDA-MB-468 xenograft model. This model
appeared to be slightly less sensitive to the drug, with the low dose
(5 mg/kg) and high dose (10 mg/kg) decreasing tumor growth by
about 45% and 52%, respectively (P,0.05; Fig. 2B1). Additionally,
there were no significant differences in body weights between
controls and animals treated with JKA97, or any gross organ
abnormalities at necropsy in either group (Figs. 2A2 and B2).
JKA97 up-regulates p21 expression in a p53-independent
manner
We next investigated the mechanism(s) of action of JKA97 by
examining its effects on the expression levels of various proteins
involved in cell cycle progression. All three cell lines were treated
with various concentrations of JKA97 for 24 hrs, Treated cells
showed increased p21 expression in a dose-dependent manner. In
addition, CyclinD1, CyclinE, and E2F1 were decreased, whereas
p27 was increased, most likely due to p21 activation (Fig. 3A). We
further treated all three cell lines with 10 mM JKA97 for varying
times, as shown in Fig. 3B. The p21 protein levels were increased
in a time-dependent manner in all cells tested, regardless of p53
status.
JKA97 has little effects on the stability of p21 protein
The effects of JKA97 on p21 regulation were also determined at
the posttranscriptional level. All three cell lines were exposed to
10 mM of JKA97 or solvent for 24 hrs followed by addition of the
protein synthesis inhibitor, cycloheximide (CHX, 10 mM). As
shown in Fig. 4A, there was no appreciable difference in p21
protein stability between cells exposed to JKA97 and those
exposed only to the solvent.
JKA97 induces p21 transcription
To determine if p21 upregulation by JKA97 resulted from
increased mRNA at the transcriptional level, all three cell lines
were treated with various concentrations of JKA97 for 24 hrs, and
the p21 mRNA expression levels were determined by real-time
PCR. Additional semi-quantification RT-PCR was employed for
consistency. As illustrated in Fig. 4B, the expression of p21 mRNA
was increased by JKA97 in a dose-dependent manner.
To further demonstrate how JKA97 affects p21 transcription, a
human full-length p21 promoter reporter was transfected into all
Figure 2. In vivo anticancer activity of JKA97 against breast cancer cells. JKA97 was administered by i.p. injection to nude mice bearing
MCF7 (A1) or MDA-MB-468 (B1) xenograft tumors. For mice bearing MCF7 xenograft tumor, treatment groups received JKA97 at doses of 5 mg/kg/
day or 25 mg/kg/day, 5 days/week, for 6 weeks; for mice bearing MDA-MB-468 xenograft tumor, treatment groups received doses at 5 mg/kg/day or
10 mg/kg/day, 5 days/week, for 18 days. Control groups received vehicle only. Animals were also monitored for changes in body weight as a
surrogate marker for toxicity when it was administered to nude mice bearing (A2) MCF7 or (B2) MDA-MB-468 xenograft tumors. At the end of the
experiments, xenograft tumors were removed and taken a photograph (A3 and B3).
doi:10.1371/journal.pone.0034303.g002
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(10 mM). As shown in Fig. 4C, the luciferase activities of the p21
reporter were significant increased by 7.1-fold, 13.4-fold, and 6.6-
fold in MCF7, MDA-MB-468, and MCF7 p53KD cells,
respectively.
Discussion
Previous studies indicate that JKA97 induced apoptosis of colon
and liver cancer cells by a p53-independent and Bax-dependent
pathway [10]. However, other possible mechanisms and the
compound’s potential for treating other cancer types have not yet
been fully elucidated. To the best of our knowledge, the present
study is the first to investigate both in vitro and in vivo anti-tumor
effects of the novel harmine benzylidene analog in human breast
cancer cells. The study highlights several important points: 1)
JKA97 significantly inhibits breast cancer cell growth; 2) JKA97
induces cell apoptosis; 3) inhibition of cell proliferation and cell
cycle progression appear to be major mechanism by which JKA97
exerts its anti-cancer effects; 4) JKA97 up-regulates p21 expression
at the transcriptional level, rather than post-transcriptional level,
independent of p53; and 5) JKA97 decreases the growth of human
breast cancer xenograft tumors in mice, in a dose-dependent
manner.
Our results indicated that there were remarkable differences in
the cell survival after JKA97 treatment, as determined by the
MTT assay, with MDA-MB-468 cells being the most sensitive
(Fig. 1B). MTT assay represents the total cell survival, which may
be affected by various factors, at least including cell proliferation,
apoptosis, and cell cycle progression. Therefore, we further
determined the effects of JKA97 on cell proliferation, apoptosis,
and cell cycle distribution. We used BrdU incorporation assay to
determine the cell proliferation index. Although there were dose-
dependent effects on cell proliferation in each of the tested cell
lines used in this study, there were no remarkable differences
between MCF7 (p53 WT) and MDA-MB-468 (p53 Mutant) cells,
indicating that the JKA97 effects on cell proliferation are p53-
independent. Interestingly, p53 KD MCF-7 cells were more
sensitive than other two cell lines (Fig. 1C). However, MDA-MB-
468 cells were shown to be more sensitive in apoptosis (Fig. 1D)
and cell cycle distribution assay (Fig. 1E). For example, at the
highest dose used (20 mM), MCF7 and MCF7 p53 KD cells
increased apoptosis similarly, but MDA-MB-468 cells were more
sensitive. Taken together, our results indicate that induction of
apoptosis and cell cycle arrest are most likely to be related to the
differences in cell survival assay among the three cell lines. The
detailed mechanisms need to be explored in the future studies.
In the present study, we also demonstrated that JKA97 had
significant in vivo anti-tumor activity in two breast cancer xenograft
models. At the 5 mg/kg dose level, we have observed the similar
responses to the therapy between the two models. Since we used
different higher doses in MCF7 and MDA-MB-468 models, it is
hard to compare the response curves. The dose used in MDA-MB-
468 model (10 mg/kg) was less than half of the dose in MCF7
model (25 mg/kg), but generated similar tumor growth inhibition
rates. We speculate that MDA-MB-468 cells are more sensitive.
Considering that there are other factors affecting the in vivo
response to JKA97 treatment, we cannot draw firm conclusion
regarding the difference between the two models. Further studies
are needed to demonstrate such differences and underlying
mechanisms.
Obstruction of cell cycle progression in cancer cells is
considered as one of the most effective strategies for the control
of tumor growth [11]. The shift from a dormant quiescent stage
(G0) to an actively growing state is a prerequisite for entry into the
cell cycle in most cells and a crucial step for cancer cells. Cell cycle
progression is modulated by regulators known as cyclin-dependent
kinase (CDK) inhibitors. The first of these proteins to be identified
and cloned is p21 [12–14]. The p21 protein, a universal cell cycle
inhibitor, binds to cyclin-CDK complexes and proliferating cell
Figure 3. Effects of JKA97 on the expression of cell cycle related proteins. (A) MCF7, MDA-MB-468, and MCF7 p53KD cells were exposed to
various concentrations of JKA97 for 24 hrs, and the expression of p53 and p21 proteins was determined by Western blot analysis. (B) Cells were
exposed to 10 mM of JKA97 for the indicated time, and the expression of p53 and p21 proteins was determined by Western blot analysis. b-actin was
used as an equal-loading control of samples.
doi:10.1371/journal.pone.0034303.g003
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cell entry into the S phase. Bearing this in mind, we checked the
relationships between G1 arrest and cell cycle related regulatory
proteins including p53, p21, and p27, after drug treatment. Our
results revealed that JKA97-mediated G1 arrest in breast cancer
cells was linked with p21, regardless of p53 status (wild-type,
mutant, or knockdown). The up-regulation of p21 and p27
proteins enhances the formation of complexes with the G1-S
CDKs and cyclins, thereby inhibiting their activities [15–17]. This
is believed to be the first report to demonstrate the mechanism of
Figure 4. Effects of JKA97 on p21 expression. (A1) MCF7, MDA-MB-468, and MCF7 p53KD cells were exposed to various concentrations of
JKA97 or vehicle for 24 hrs, followed by exposure to protein synthesis inhibitor cycloheximide (CHX, 10 mg/mL). p21 protein expression was detected
by Western blotting at different times after exposure of CHX. (A2) The graph shows the quantification of the Western blotting data. MCF7 (B1), MDA-
MB-468 (B2) and MCF7 p53KD (B3) Cells were exposed to various concentrations of JKA97 or vehicle for 24 hrs, and total RNA were extracted
followed by reverse transcription, and detection mRNA level of p21 by Real-time quantification PCR and Quantification RT-PCR, normalized by mRNA
level of GAPDH. (C) Cells were transfected with p21 promoter luciferase reporter plasmid and a Renilla luciferase reporter together for 12 hrs,
followed by treatment of 10 mM JKA97 or vehicle for an additional 24 hrs. The reporter activity was normalized to the corresponding Renilla luciferase
reporter. The luciferase assay was performed in triplicate. Statistical significance was determined compared with control (*P,0.05).
doi:10.1371/journal.pone.0034303.g004
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cancer cells. Our study further demonstrated that up-regulation of
p21 induced by JKA97 was mainly dependent on a transcriptional
mechanism rather than a post-translational alteration. Future
studies should examine the underlying mechanisms concerning
how JKA97 up-regulates p21 transcription and influences the
downstream pathways.
Many researchers have suggested that cell cycle arrest and
apoptosis may be linked. Molecules acting on cells in G1 phase are
normally thought to affect apoptosis; CDK inhibitors have been
suggested to be indirectly involved in apoptosis through regulation
of CDKs. p21, a major CDK inhibitor, is induced by both p53-
dependent and -independent mechanisms following stress [18].
Additionally, it is reported that overexpression of p21 results in an
induction of Bax and promotes apoptosis [19]. Considering that
Luo et al. [10] have demonstrated that JKA97 can induce apoptosis
in colon cancer cells in a Bax-dependent but p53-independent
manner, further work is required to correlate the relationship
between the cell cycle arrest and apoptosis pathways regulated by
the compound.
The observations from the present study provided rational
evidence for the use of JKA97 as an anti-tumor agent for human
breast cancer therapy. Our results, taken in conjunction with
earlier results for this compound, indicate that the anti-cancer
activity of JKA97 is inextricably linked with modulation of p21.
Further studies involving p21 deficient systems would be required
to fully gauge the extent of involvement of this important protein.
The present study, together with previous reported findings [10],
will surely improve our understanding of the mechanisms of action
of JKA97, providing a basis for further preclinical and clinical
evaluation of the compound as a novel anti-cancer agent.
Materials and Methods
Test Compound, Chemicals and Reagents
The test compound JKA97, methoxy-1-styryl-9H-pyrido-[3,4-
b]-indole, was synthesized and purified as previously reported
[10], and the structure was confirmed by UV, IR, MS, and NMR
spectroscopy [10]. The purity of the test compound was
determined to be greater than 95% by HPLC and MS analyses.
All chemicals and solvents used were of analytical grade or the
highest grade available. Cell culture supplies such as culture
media, phosphate-buffered saline (PBS), fetal bovine serum (FBS),
sodium pyruvate, non-essential amino acids, and penicillin-
streptomycin were obtained from Invitrogen (Carlsbad, CA).
Antibodies against human p21 (C-19), p27 (C-19), Cyclin D1
(DCS-6), Cyclin E (HE12), and E2F1 (KH95) were from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). The anti-human p53
antibody (Ab-6) was from EMD Chemicals, Inc. (Gibbstown, NJ).
The anti-human b-actin antibody (T5168) was from Sigma-
Aldrich (St. Louis, MO).
Cell lines and Culture
Human breast cancer MCF7 and MDA-MB-468 cells were
obtained from the American Type Culture Collection (Rockville,
MD). MCF7 and MDA-MB-468 cells were grown in MEM media
containing 1 mM non-essential amino acids and Earle’s BSS,
1 mM sodium pyruvate and 10 mg/L bovine insulin, and
DMEM/F-12 Ham’s media (DMEM/F-12 1:1 mixture). MCF7
p53KD cells were generated by using the method described
previously [20,21] and were grown in the same media as MCF7
cells, but supplemented with 0.5 mg/mL puromycin (Sigma; St.
Louis, MO). All cell culture media contained 10% FBS and 1%
penicillin/streptomycin, unless otherwise specified.
Cell Survival Assay
The effects of JKA97 on human breast cancer cell growth were
determined by using the MTT assay and expressed as the
percentages of control cell survival [22–25]. The cells were grown
in 96-well plates, seeding at a density of 4–5610
3 cells per well,
and exposed to various concentrations of the test compound (0 to
50 ı `M) for 72 hrs. 10 mL of the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) solution (5 mg/mL; Sigma;
St. Louis, MO) were then added. The absorbance at 570 nm was
recorded by using a SYNERGY Mx microplate reader (BioTek,
Winooski, VT). The cell survival rates (%) were calculated by
dividing the mean OD of compound-containing wells by that of
control wells.
Cell Proliferation Assay
The effects of JKA97 on cell proliferation were determined by
the BrdUrd incorporation assay (Oncogene, La Jolla, CA),
following the manufacturer’s protocol. Cells were seeded in 96-
well plates (8610
3 to 1.2610
4 cells per well) and incubated with
various concentrations of JKA97 (0, 5, 10 and 20 ı `M) for 48 hrs.
BrdUrd was added to the medium 10 hrs before termination of the
experiment. The BrdUrd incorporated into cells was determined
by anti-BrdUrd antibody, and the absorbance was measured at
dual wavelengths of 450/540 nm with a SYNERGY Mx
microplate reader (BioTek, Winooski, VT).
Detection of Apoptosis
Cells in early and late stages of apoptosis were detected using an
Annexin V-FITC apoptosis detection kit from BioVision (Moun-
tain View, CA). In brief, 4–5610
5 cells per well were exposed to
the test compound (0, 5, 10 and 20 mM) and incubated for 24 hrs
prior to analysis. Cells were collected and washed with serum-free
media, then re-suspended in 500 mL of Annexin V binding buffer,
followed by addition of 5 mL of Annexin V-FITC and 5 mLo f
propidium iodide (PI). The samples were incubated in the dark for
5 min at room temperature and analyzed with a FACSCaliber
flow cytometer (BD Biosciences, San Jose, CA).
Cell Cycle Measurements
To determine the effects of JKA97 on cell cycle distribution, 4–
5610
5 cells per well were exposed to the compound (0, 5, 10, and
20 ı `M) and incubated for 24 hrs prior to analysis. Cells were
harvested and fixed in 75% ethanol at 4uC overnight, followed by
incubation with RNAse and staining with propidium iodide
(Sigma). The DNA content was determined by flow cytometry as
indicated above.
Mouse Xenograft Model of Human Breast Cancer
The animal use and care protocol was approved by the
Institutional Animal Use and Care Committee of the Texas Tech
University Health Sciences Center (IACUC # 10032, PHS
Assurance # A 3056-01, USDA Registration # 74-R-0050, REF
# 039461). Female athymic pathogen-free nude mice (nu/nu, 4–6
weeks) were purchased from Charies River Laboratories Interna-
tional, Inc. (Wilmington, MA). To establish MCF7 human breast
cancer xenograft tumor model, each of the female nude mice was
first implanted with a 60-day subcutaneous slow release estrogen
pellet (SE-121, 1.7 mg 17b-estradiol/pellet) obtained from Inno-
vative Research of America (Sarasota, FL). On the following day,
MCF-7 cells harvested from monolayer cultures were washed
twice with serum-free medium, re-suspended in the medium, and
then injected s.c. (5610
6 cells, total volume 0.2 mL) into the left
inguinal area of the mice. For the MDA-MB-468 xenograft model,
JKA97 for Treatment of Breast Cancer
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pellet. All animals were monitored for activity, physical condition,
body weight, and tumor growth. Tumor size was determined every
other day by caliper measurement of two perpendicular diameters
of the implant. Tumor mass (in g) was calculated by the formula,
1/2a6b
2 where ‘‘a’’ is the long diameter and ‘‘b’’ is the short
diameter (in cm).
In vivo chemotherapy with JKA97
The animals bearing human cancer xenograft tumors were
randomly divided into various treatment groups and a control
group (7–10 mice/group). The control groups for both models
received the vehicle only. For the MCF7 xenograft model, JKA97
was dissolved in the vehicle, PEG400: ethanol: saline
(57.1:14.3:28.6, v/v/v), and was administered by i.p. injection at
doses of 5 and 25 mg/kg/d, 5 days/wk for about 3 weeks. For the
MDA-MB-468 xenograft model, JKA97 was administered by i.p.
injection at doses of 5 and 10 mg/kg/d, 5 days/wk for 6 weeks. At
the end of the experiments, xenograft tumors were removed,
weighed, and photographed for records.
Western Blot Analysis
The protein levels in cell lysates were assessed using Western
blotting as described previously [20,21]. In brief, cells were
exposed to various concentrations of JKA97 for 24 hrs and cell
lysates were fractionated with identical amounts of protein by
SDS-PAGE. The proteins were transferred to Bio-Rad trans-Blot
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA)
that were then incubated in blocking buffer (Tris-buffered saline
containing 0.1% Tween 20 and 5% nonfat milk) for 1 hr at room
temperature. Then the membranes were incubated with the
appropriate primary antibodies overnight at 4uC or 2 hrs at room
temperature, with gentle shaking. The membranes were washed
with rinsing buffer (Tris-buffered saline containing 0.1% Tween
20) thrice for 15 min and then incubated with the goat anti-
mouse/-rabbit IgG-horseradish peroxidase-conjugated antibody
(Bio-Rad) for 1 hr at room temperature. After washing thrice, the
proteins of interest were detected by using enhanced chemilumi-
nescence reagents from PerkinElmer LAS, Inc (Boston, MA).
RNA extraction, and semi-quantitative and real-time
quantitative RT-PCR
Total RNA was extracted by using the Trizol reagent from
Invitrogen (Carlsbad, CA). First-strand cDNA was synthesized
with 1 mg of total RNA extract using the iScript cDNA synthesis
kit (Bio-Rad, Hercules, CA). The primer sequences used for
amplification of genes were as follows: p21 forward, 59-AGC AGC
GGA ACA AGG AGT-39, reverse, 59-TGG AGA AAC GGG
AAC CAG-39; GAPDH forward, 59-GGA GTC CAC TGG CGT
CTT CAC-39, reverse, 59-GAG GCA TTG CTG ATG ATC
TTG AGG-39. Semi-quantitative RT-PCR was performed with
mixture of the cDNA product, primers, dNTP and Taq DNA
polymerase (Invitrogen) using cycles of 95uC for 30 s, 57uC for
30 s, and 72uC for 30 s, followed by a final extension at 72uC for
5 min. Real-time PCR was performed for 40 cycles consisting of
95uC for 20 s, 57uC for 20 s and 72uC for 20 s using an iQ5
machine (Bio-Rad, USA). All samples were analyzed by the
comparative threshold cycle (CT) method and normalized to the
GAPDH mRNA control.
Luciferase Assay
Cells were cotransfected with full-length human p21 promoter
vectors with Renilla luciferase reporter (as internal control;
Promega, Madison, WI) for 24 hrs, followed by incubation with
JKA97 for 24 hrs. The luciferase activity of the p21 promoter
reporter was determined with the Dual-Luciferase Reporter Assay
System (Promega, Madison, WI) according to the manufacturer’s
instructions. The p21 reporter activity was normalized to the
corresponding Renilla luciferase reporter activity.
Statistical Analysis
Data of different treatment groups are presented as means 6
standard errors. One-way ANOVA followed by S-N-K post hoc
test was used to determine the significance of the differences
among treatment groups and controls. Results were considered
statistically significant when P,0.05.
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